About: Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19
Creator	Torres, Maria Brockow, Knut Atanaskovic-Markovic, Marina Barbaud, Annick Doña, Inmaculada Gelincik, Aslı Mayorga, Lina Romano, Antonino Soyer, Özge
topic	covid:bccee71a829a48fc064a20b61491f56c5f45d286#this
source	Medline; PMC
abstract	Coronavirus disease 2019 (COVID‐19), a respiratory tract infection caused by a novel human coronavirus, the severe acute respiratory syndrome coronavirus 2, leads to a wide spectrum of clinical manifestations ranging from asymptomatic cases to patients with mild and severe symptoms, with or without pneumonia. Given the huge influence caused by the overwhelming COVID‐19 pandemic affecting over three million people worldwide, a wide spectrum of drugs is considered for the treatment in the concept of repurposing and off‐label use. There is no knowledge about the diagnosis and clinical management of the drug hypersensitivity reactions that can potentially occur during the disease. This review brings togetherall the published information about the diagnosis and management of drug hypersensitivity reactions due to current and candidate off‐label drugs andhighlights relevant recommendations. Furthermore, it gathers all the dermatologic manifestations reported during the disease for guiding the clinicians to establish a better differential diagnosis of drug hypersensitivity reactionsin the course of the disease.
has issue date	2020-06-08(xsd:dateTime)
bibo:doi	10.1111/all.14439
bibo:pmid	32511784
has license	no-cc
sha1sum (hex)	bccee71a829a48fc064a20b61491f56c5f45d286
schema:url	https://doi.org/10.1111/all.14439
resource representing a document's title	Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19
has PubMed Central identifier	PMC7300843
has PubMed identifier	32511784
schema:publication	Allergy
resource representing a document's body	covid:bccee71a829a48fc064a20b61491f56c5f45d286#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/bccee71a829a48fc064a20b61491f56c5f45d286
is schema:about of	named entity 'reactions' named entity 'mild' named entity 'spectrum' named entity 'coronavirus' named entity 'respiratory tract' named entity 'Given' named entity 'patients' named entity 'dermatologic' named entity 'human' named entity 'off-label' named entity 'severe' named entity 'caused' named entity 'manifestations' named entity 'drug' named entity 'dermatologic' named entity 'COVID' named entity 'disease' named entity 'drug' named entity 'Baricitinib' named entity 'dermatological' named entity 'thrombotic' named entity 'canakinumab' named entity 'COVID' named entity 'ADRs' named entity 'Acute Generalized Exanthematous Pustulosis' named entity 'viral infections' named entity 'drug-related' named entity 'etiological' named entity 'Heparin' named entity 'ribavirin' named entity 'solubility' named entity 'COVID' named entity 'lactose' named entity 'ADRs' named entity 'Intravenous' named entity 'Italy' named entity 'platelets' named entity 'anti-parasitic' named entity 'receptor' named entity 'NIHR' named entity 'UFH' named entity 'complement activation' named entity 'Gastrointestinal symptoms' named entity 'maculopapular' named entity 'urticaria' named entity 'chemical group' named entity 'lactose' named entity 'IgE' named entity 'erythematous rash' named entity 'COVID-19' named entity 'nucleic acid testing' named entity 'micromolar' named entity 'HIV' named entity 'LMWH' named entity 'COVID' named entity 'ADRs' named entity 'azithromycin' named entity 'tofacitinib' named entity 'DIC' named entity 'ribavirin' named entity 'erythematous rash' named entity 'Heparin' named entity 'oseltamivir' named entity 'cutaneous' named entity 'COVID-19' named entity 'thrombosis' named entity 'urticaria' named entity 'COVID' named entity 'MERS-CoV' named entity 'AGEP' named entity 'oxygen support'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software